Recursion Pharmaceuticals Inc. (RXRX) News

Recursion Pharmaceuticals Inc. (RXRX): $13.37

1.63 (-10.87%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

Filter RXRX News Items

RXRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RXRX News Highlights

  • For RXRX, its 30 day story count is now at 10.
  • Over the past 16 days, the trend for RXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about RXRX are DRUG, DEC and RARE.

Latest RXRX News From Around the Web

Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.

40 Cities with the Highest Life Expectancy in the US

In this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US. Life expectancy of a newborn […]

Yahoo | December 22, 2023

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries w

Yahoo | December 20, 2023

3 Genomics Stocks to Unlock the Future of Medicine

Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.

Jeremy Flint on InvestorPlace | December 19, 2023

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

These two biotech stocks hold enormous potential.

Yahoo | December 17, 2023

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023

Insider Sell: CFO Michael Secora Sells 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX)

In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on December 13, 2023.

Yahoo | December 15, 2023

Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock

Wood is moving away from fintech and Internet names like COIN stock.

Dana Blankenhorn on InvestorPlace | December 14, 2023

Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future

Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently forecasts about 23% upside potential in the next 12 months. Plus, Recursion’s strategic partnership with some big names, including NVIDIA (NASDAQ:NVDA), to revolutionize AI in drug discovery has Wall Street optimistic about its long-term potential. Recursion’s commitment to tackling rare diseases will drive i

Yahoo | December 14, 2023

These 9 Micro/Small Cap AI Stocks Continue In Bubble Mode

9 micro/small cap AI stocks are still in bubble mode advancing 14.8%, on average, last week. In comparison, the Global X Artificial Intelligence & Technology ETF was only up 0.5% and the iShares Semiconductor ETF was only up 1.6%.

TalkMarkets.com | December 12, 2023

Insider Sell: CEO Christopher Gibson Disposes of 59,829 Shares of Recursion Pharmaceuticals Inc ...

In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023.

Yahoo | December 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!